ArticleCell communication and signaling : CCS2025
Conjugated bile acids promote metabolic dysfunction-associated steatotic liver disease through inducing nuclear translocation of sphingosine-1-phosphate receptor 2 to disrupt peroxisome proliferator-activated receptor alpha.
Article in Cell communication and signaling : CCS, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Bile acid signaling in health and disease.Molecular biomedicine · 2026Review
- Gut microbiome and bile acid metabolism in liver disease: Mechanisms, clinical implications, and therapeutic opportunities.Pharmacological reviews · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
14 authors.
Funding
Abstract
backgroundConjugated bile acids (CBAs) induced metabolic dysfunction-associated steatotic liver disease (MASLD) through activating sphingosine-1-phosphate receptor 2 (S1PR2). However, the precise mechanisms have not been fully understood.
methodsWe established a link between CBAs and MASLD in IBD patients with high SphK2 and Villin-SphK2TG mice. Villin-SphK2TG mice were fed high-fat diet (HFD) for inducing MASLD. Gut microbiota composition was analyzed by 16 S rDNA Amplicon sequencing assay. We performed the UPLC/TQMS based targeted metabolomics assay to analyze the compositions of BAs in liver, serum and feces. In vitro assays, hepatocytes transfected with N-terminal truncated-S1PR2 analyzed the dynamics of S1PR2 stimulated by CBAs. PPARα function was assayed by analyzing the DNA-protein interactions by using Electrophoretic mobility shift assay (EMSA).
resultsThe IBD patients with high colonocyte SphK2 conferred the development of MASLD. Feeding high-fat diet, Villin-SphK2TG mice developed MASLD more severely than WT mice. Analysis of gut microbiota showed that colonic SphK2 shaped microbiota by reducing the BSH-producing bacteria, thus leading to the accumulation of CBAs in liver via the gut-liver axis. CBAs induced nuclear translocation of S1PR2 through cleavage the N-terminal sequences of Ala-Ser-Ala-Phe-Iso in hepatocytes. Cleaved S1PR2 (S1PR2') was thus translocated into the nucleus to bind with PPARα, thereby interdicting the function of PPARα in regulating the genes involved in lipid catabolism. S1PR2 antagonist JTE-013 blocked the CBAs-induced nuclear translocation of S1PR2 and S1PR2 is thus identified as a potential therapeutic target for MASLD treatment.
conclusionCBAs promoted MASLD through inducing S1PR2 translocation into the nucleus, where it bound PPARα to interdict the function of PPARα in regulating genes involved in lipid catabolism.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.